Intention notice: 2599q riluzol

Sykehusinnkjøp HF intends, on behalf of the four regional health authorities, to enter into a framework agreement with Teva Norway AS from and including 1 May 2025 on the delivery of the medicine Riluzol Actavis soluble tablets for the treatment of the disease amyotrophic lateral sclerosis (ALS). ALS is a …

CPV: 33600000 Productos farmacéuticos
Lugar de ejecución:
Intention notice: 2599q riluzol
Organismo adjudicador:
SYKEHUSINNKJØP HF
Número de premio:
2024/1439

1. Buyer

1.1 Buyer

Official name : SYKEHUSINNKJØP HF

2. Procedure

2.1 Procedure

Title : Intention notice: 2599q riluzol
Description : Sykehusinnkjøp HF intends, on behalf of the four regional health authorities, to enter into a framework agreement with Teva Norway AS from and including 1 May 2025 on the delivery of the medicine Riluzol Actavis soluble tablets for the treatment of the disease amyotrophic lateral sclerosis (ALS). ALS is a rare progressive nerve disease that causes gradual wastage of motor nerves in the cerebral cortch and spinal cord. There is no treatment that can cure the disease, but there is one registered medicine that can give prolonged survival for this patient group. Reasons for awarding the contract without a competition notice: The manufacturer of the original medicine (Sanofi) notified Sykehusinnkjøp HF in April 2024 that they will stop the production of Rilutek tablets (riluzol) starting May 2 024.On this occasion Sykehusinnkjøp has undertaken market surveys and noted that there is only one tenderer with marketing authorisation in the EU/EEA for medicines with the active ingredient riluzole tablets that are willing to assist with deliveries to norwegian Market. The contracting authority therefore believes that it is necessary to enter into a contract without a competition in accordance with the procurement regulations § 13-4 first section, letter b no. 2. The framework agreement is planned to be signed 10 days after publication of the intention notice. The contract has an estimated annual value of NOK 3,400,000 excluding VAT and a maximum value of NOK 3,400,000. NOK 13,600,000 excluding VAT. The framework agreement will be valid for two years, with an option for an extension for up to 24 months.
Procedure identifier : 2fa0b61b-8c44-4e0f-8f01-1c4abf1a94a2
Internal identifier : 2024/1439
Type of procedure : Negotiated without prior call for competition

2.1.1 Purpose

Main nature of the contract : Supplies
Main classification ( cpv ): 33600000 Pharmaceutical products

2.1.2 Place of performance

Country : Norway
Anywhere in the given country

2.1.4 General information

Legal basis :
Directive 2014/24/EU
Anskaffelsesforskriften -

5. Lot

5.1 Lot technical ID : LOT-0000

Title : Intention notice: 2599q riluzol
Description : Sykehusinnkjøp HF intends, on behalf of the four regional health authorities, to enter into a framework agreement with Teva Norway AS from and including 1 May 2025 on the delivery of the medicine Riluzol Actavis soluble tablets for the treatment of the disease amyotrophic lateral sclerosis (ALS). ALS is a rare progressive nerve disease that causes gradual wastage of motor nerves in the cerebral cortch and spinal cord. There is no treatment that can cure the disease, but there is one registered medicine that can give prolonged survival for this patient group. Reasons for awarding the contract without a competition notice: The manufacturer of the original medicine (Sanofi) notified Sykehusinnkjøp HF in April 2024 that they will stop the production of Rilutek tablets (riluzol) starting May 2 024.On this occasion Sykehusinnkjøp has undertaken market surveys and noted that there is only one tenderer with marketing authorisation in the EU/EEA for medicines with the active ingredient riluzole tablets that are willing to assist with deliveries to norwegian Market. The contracting authority therefore believes that it is necessary to enter into a contract without a competition in accordance with the procurement regulations § 13-4 first section, letter b no. 2. The framework agreement is planned to be signed 10 days after publication of the intention notice. The contract has an estimated annual value of NOK 3,400,000 excluding VAT and a maximum value of NOK 3,400,000. NOK 13,600,000 excluding VAT. The framework agreement will be valid for two years, with an option for an extension for up to 24 months.
Internal identifier : 2024/1439

5.1.1 Purpose

Main nature of the contract : Supplies
Main classification ( cpv ): 33600000 Pharmaceutical products
Options :
Description of the options : The framework agreement will be valid for two years, with an option for an extension for up to 1 year at a time. The total maximum agreement period is 4 years.

5.1.2 Place of performance

Country : Norway
Anywhere in the given country
Additional information :

5.1.3 Estimated duration

Start date : 01/05/2025
Duration end date : 30/04/2027

5.1.6 General information

Procurement Project not financed with EU Funds.
The procurement is covered by the Government Procurement Agreement (GPA) : yes

5.1.10 Award criteria

Criterion :
Type : Price
Name :
Description :
Weight (percentage, exact) : 100
Description of the method to be used if weighting cannot be expressed by criteria :
Justification for not indicating the weighting of the award criteria :

5.1.16 Further information, mediation and review

Review organisation : Indre og Østre Finnmark tingrett, rettssted Vadsø

6. Results

6.1 Result lot ldentifier : LOT-0000

6.1.2 Information about winners

Winner :
Official name : Teva Norway AS
Tender :
Tender identifier : Tilbud: 2599q riluzol
Identifier of lot or group of lots : LOT-0000
Subcontracting value is known : no
Subcontracting percentage is known : no
Contract information :
Identifier of the contract : Kontrakt: 2599a riluzol
The contract is awarded within a framework agreement : no

8. Organisations

8.1 ORG-0001

Official name : SYKEHUSINNKJØP HF
Registration number : 916879067
Postal address : Postboks 40
Town : VADSØ
Postcode : 9811
Country subdivision (NUTS) : Troms og Finnmark ( NO074 )
Country : Norway
Contact point : Postmottak Sykehusinnkjøp
Telephone : +47 78950700
Roles of this organisation :
Buyer
Central purchasing body acquiring supplies and/or services intended for other buyers

8.1 ORG-0002

Official name : Indre og Østre Finnmark tingrett, rettssted Vadsø
Registration number : 926722840
Town : Vadsø
Country : Norway
Telephone : 78011700
Roles of this organisation :
Review organisation

8.1 ORG-0003

Official name : Teva Norway AS
Registration number : 982222311
Town : Sandvika
Country : Norway
Telephone : 66775590
Roles of this organisation :
Tenderer
Winner of these lots : LOT-0000

11. Notice information

11.1 Notice information

Notice identifier/version : fd5c4f1e-3a0b-48c4-bd76-3adcb4879354 - 01
Form type : Direct award preannouncement
Notice type : Voluntary ex-ante transparency notice
Notice dispatch date : 07/11/2024 12:53 +00:00
Notice dispatch date (eSender) : 07/11/2024 12:58 +00:00
Languages in which this notice is officially available : English

11.2 Publication information

Notice publication number : 00682667-2024
OJ S issue number : 218/2024
Publication date : 08/11/2024